Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome

February 12, 2019 updated by: University of Sao Paulo General Hospital

Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome: Randomized Blind Clinical Trial

INTRODUCTION: Overactive bladder syndrome is defined by The International Continence Society as urgency, with or without incontinence, usually with increased urinary frequency and nocturia. It is difficult to estimate the prevalence of this syndrome because many patients do not seek medical help, despite considerable negative impact on quality of life. Lower urinary tract dysfunctions can be treated using electrical stimulation of the posterior tibial nerve. This therapy is conservative, effective, inexpensive and promotes high adhesion to treatment. It has good results, decreasing symptoms of urgency, urge-incontinence, urinary frequency and nocturia . Due to lack of consensus on the parameters of this technique, further research is necessary. OBJECTIVE: To compare the effectiveness of protocols for the electrical stimulation of the posterior tibial nerve for treatment of non-neurogenic overactive bladder. METHODS: The study was a blind randomized clinical trial. The study will accept up to 145 women with overactive bladder diagnosis for at least six months prior to the beginning of the study. The subjects will be divided into five groups: group TENS 0-1 (placebo group), group TENS 1-1 (electrical stimulation of one leg once a week), group TENS 1-2 (electrical stimulation of one leg twice a week), group TENS 2-1 (electrical stimulation of two legs one a week) and group TENS 2-2 (electrical stimulation of two legs twice a week). Physical evaluation will be done at the beginning and at the end of the treatment. Evaluation will be done using the King "s Health Questionnaire, the International Consultation Incontinence Questionnaire - Short Form, the Overactive Bladder Questionnaire, a three day urinary diary and a table for follow-up treatment.

Study Overview

Detailed Description

Participants will be recruited from Urogynecology Physical Therapy Outpatient Clinic of a university hospital and randomly assigned using website www.randomization.com and distributed into five groups considering the sites of application and frequency of attendanc, listed above.

Data will be collected by the investigator using interview and physical examination and will be safely stored in computer.

For this study, in terms of urinary frequency, the standard deviation was estimated at 3.25 episodes of urinary urgency (SD=3.25). With 80% power and 95% confidence, the sample size calculation was 25 women in each group, plus a possible sample loss of around 20%, resulting in a sample size of 29 women per group, for a total of 145 patients in the study.

The chi-square test was used to assess whether there was an association between sample description variables and treatments. The analysis of variance F-test was used to assess whether there were differences in the numerical descriptive variables between treatment groups. The nonparametric Kruskal-Wallis test was used to compare treatments in terms of the difference between before and after for each quality of life and voiding diary variables. If there was statistical significance, the Dunn multiple comparison test was performed, with p-values of less than 0.05 considered significant. The analysis of variance model with repeated measures was used to compare data from the specific voiding diary according to the treatment groups and sessions. Significant comparisons were evaluated with Tukey post-hoc test. To approximate data to the normality, a 1/log (variable+1) transformation was done. For the follow up analysis, it was used the ANOVA three ways, with Holm Sidak post-hoc test for comparison of scores. All the statistical tests developed were based on a significance of 5%, i.e., the null hypothesis was rejected when the p-value was less than 0.05.

Study Type

Interventional

Enrollment (Actual)

145

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sao Paulo, Brazil, 05403000
        • Gynecology Ambulatory of the General Hospital of the Faculty of Medicine of the University of Sao Paulo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women with 18 years of age or more;
  • Cognitive level adequate for understanding orientations during treatment;
  • Clinical diagnosis of overactive bladder syndrome for at least six months prior to the study.

Exclusion Criteria:

  • Pregnant women or women who wish to get pregnant;
  • Neurological disease;
  • Urinary infection;
  • Nephrolithiasis;
  • Stress urinary incontinence;
  • Mixed urinary incontinence;
  • Women in pharmacological treatment for overactive bladder syndrome;
  • Women undergoing hormone replacement therapy in the last six months;
  • Peripheral neuropathy;
  • Cystocele stage two or higher.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Group TENS 0-1
Electrodes will be fixated to one leg and sessions will be held once a week.
Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
Experimental: Group TENS 1-1
Electrical stimulation of the posterior tibial nerve of one leg once a week.
Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
Experimental: Group TENS 1-2
Electrical stimulation of the posterior tibial nerve of one leg twice a week.
Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
Experimental: Group TENS 2-1
Electrical stimulation of the posterior tibial nerve of two legs once a week.
Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
Experimental: Group TENS 2-2
Electrical stimulation of the posterior tibial nerve of two legs twice a week.
Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in urinary frequence in 12 sessions.
Time Frame: The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.
Number of micturitions per day.
The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Nocturia in 12 sessions.
Time Frame: The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.
Number of micturitions per night, interrupting sleep.
The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.
Change in urinary urgence in 12 sessions.
Time Frame: The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.
Number of urgent micturitions per day.
The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.
Change in urinary urge-incontinence in 12 sessions.
Time Frame: The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.
Number of leaks per day.
The patients fill in a bladder diary of 3 days running. One bladder diary starting in the first session and the last one to end in the last session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Elizabeth AG Ferreira, PhD, Faculty of Medicine, University of São Paulo, São Paulo, Brazil

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 9, 2013

Primary Completion (Actual)

August 25, 2014

Study Completion (Actual)

September 25, 2014

Study Registration Dates

First Submitted

June 5, 2013

First Submitted That Met QC Criteria

July 29, 2013

First Posted (Estimate)

July 31, 2013

Study Record Updates

Last Update Posted (Actual)

February 15, 2019

Last Update Submitted That Met QC Criteria

February 12, 2019

Last Verified

December 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overactive Bladder Syndrome

Clinical Trials on TENS 0-1

Subscribe